Between mid-October and early January, Nuvalent’s Chief Scientific Officer Deborah Ann Miller reduced her stake by 8.9%, selling a total of 81,062 shares across six transactions. The most recent sale on January 5th involved 4,363 shares for approximately $425,000, bringing her remaining position to 44,723 shares. Over the prior quarter she executed five additional disposals, including 24,200 shares on November 17th and 21,800 shares on October 30th, signaling a sustained pattern of liquidity harvesting by a senior executive.

Despite Miller’s divestitures, 15 of 16 analysts maintain a buy or overweight stance on Nuvalent, with consensus targets clustering around a mid-three-digit dollar range. Over the past two months, Stifel Nicolaus and Robert W. Baird have both raised their targets, while JPMorgan Chase adjusted its outlook slightly downward but retained an overweight recommendation. Institutional research forecasts Nuvalent’s full-year loss per share to widen modestly, reflecting ongoing pre-commercial R&D investment.

Nuvalent remains a clinical-stage precision oncology company headquartered in San Diego, applying structure-guided design to develop small-molecule inhibitors. Its lead candidates, NVL-520 (RET inhibitor) and NVL-655 (KRAS G12D inhibitor), are advancing through early clinical trials. With a recent market capitalization exceeding $7.5 billion and a beta above 1.3, the firm’s valuation reflects investor confidence in near-term data readouts and its ability to address genetically defined cancer populations.